Back to the journal
RegDataLab Team

FDA Warning Letters in October 2026: 8 Drug Makers Warned Without an Inspection

3 min read

FDA dated 46 warning letters in October 2026, not counting tobacco retailers. September had 33. Eight of October’s letters went to drug makers FDA never visited. The count can still grow, because FDA posts some letters weeks after their date.

Where the 46 went

GroupLetters
Unapproved or misbranded drugs19
Drug manufacturing (CGMP)14
Refusing to give FDA records2
Food importers (FSVP)3
Medical devices4
Food and supplements2
Other (lab practice, animal drugs)2

The groups follow the subject line FDA gives each letter. Counts are as of November 12, 2026.

Eight letters, no inspection

Eight of the drug letters went to makers FDA did not visit. FDA asked for records under its records request power, read them, and wrote the letter. Seven of the eight firms are in China and one is in Singapore.

Two of them, Tianjin Healthcare Medical Technology and Guangdong Bisutang Biotechnology, were warned for not sending the records at all. FDA treats that the same way as refusing an inspection.

For anyone who qualifies suppliers, this changes one old assumption. “FDA rarely gets to that site” no longer means the site is out of reach. A records request can become a public warning letter within months.

Ten letters in one day

On October 1, FDA dated ten letters for unapproved drugs. Two of them went to Amazon and Walmart.

Recalls and inspections

  • Class I recalls, the most serious class: 4 so far, against 37 in September. One firm, Par Health USA, accounts for two of them (particulate matter in drug products).
  • Inspections classed OAI, where FDA recommends action: 2 posted so far. Classifications trail the inspection by weeks, so this number is early.
  • A new entry among the most-cited Form 483 items: supplier performance not monitored (ISO 13485 clause 7.4.1), cited 5 times.

Three checks to run on a supplier this month

  1. Any warning letter in the last three years, and whether FDA has posted a close-out letter for it.
  2. The last inspection result (NAI, VAI or OAI), and whether an OAI was followed by a clean reinspection.
  3. Import alert status. For drug sites, Import Alert 66-40.

All three are public on fda.gov. The free company check pulls them for a whole company family in one search.

Every letter and recall counted here is listed, with its fda.gov link, on the October 2026 page.

The 46 warning letters are also a free dataset you can cite, as a CSV under a CC0 license: doi.org/10.5281/zenodo.24175571. It reflects the count on November 12, 2026.